Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: The field of AI and machine learning is undergoing explosive development and growth, yet the timing of impact in the area of health care and health management as a key element in the clinical care is still uncertain. How AI will influence our approaches to the management of complex diseases such as cancer, what elements of technologies will come into play, and how this be impacted in a regulated setting remains to be seen. Clearly, we will see many rewards with AI in the clinic, but we first must anticipate the hurdles along to way and devise solutions to overcome them.
Session Chair Profile
CEO and Chairperson, N-of-One
Christine Cournoyer is Chief Executive Officer of N-of-One. Prior to joining N-of-One, she was President and Chief Operating Officer of Picis, a leading company in the healthcare IT market. Picis provided software solutions that bridge revenue cycle and clinical workflow management for high-acuity operations within hospitals, including emergency rooms, operating rooms, and critical care. Picis’ systems were installed in more than 1,800 medical centers, hospitals, and integrated delivery networks in 19 countries around the world. Ms. Cournoyer served as President and Chief Operating Officer of Lightbridge, Inc. and held senior management positions at IBM, including Vice President of Business Transformation as well as Chief Information Officer of IBM’s software group. She also served as Senior Vice President at Lotus Development. Ms. Cournoyer was named one of the “10 Most Influential Women in Technology” by Businessweek. She is currently a Corporator for Emerson Hospital and a member of both the Boston Club and the Women Corporate Directors.
M.D., Co-Founder & CEO, PathAI
Andy earned his MD from Brown Medical School and completed residency and fellowship training in Anatomic Pathology and Molecular Genetic Pathology from Stanford University. He completed a PhD in Biomedical Informatics from Stanford University, where he developed one of the first machine-learning based systems for cancer pathology. He is board certified by the American Board of Pathology in Anatomic Pathology and Molecular Genetic Pathology. Prior to co-founding PathAI, he was on the faculty of Harvard Medical School in the Department of Pathology at Beth Israel Deaconess Medical Center. He has published over 110 papers in the fields of cancer biology, cancer pathology, and biomedical informatics.
Presentation Title and Company Description
AI Showcase: Artificial Intelligence for Precision Cancer Pathology
PathAI, formed in 2016 in Cambridge, MA, is the world’s leading computational pathology company. We use artificial intelligence to improve the health of people around the world by enhancing the predictive power of pathologic diagnoses and accelerating the development of novel therapies. We serve partners in the pharmaceutical industry, in the clinical laboratory, and in global health.
Ph.D., Director, Miami Cancer Institute; Director, Translational Research and Genomic Medicine, Baptist Health South Florida
Jeff Boyd is a professor and chair at Florida International University and the Director of Translational Research and Genomic Medicine at the Miami Cancer Institute. Previously, Dr. Boyd was the Senior Vice President at Fox Chase Cancer Center. Before joining Fox Chase, Dr. Boyd was the vice president for Oncology and Research at Memorial Health, and director of the Curtis & Elizabeth Anderson Cancer institute. Boyd came to Savannah from Memorial Sloan-Kettering Cancer Center in New York City, where he served as an attending biologist and director of the gynecology and breast research laboratory in the Department of Surgery and director of the diagnostic molecular genetics laboratory in the Department of Medicine. Boyd has received more than 14 National Institutes of Health or NIH-equivalent research grants totaling several million dollars. He has served on the editorial boards of five prestigious journals, including the American Journal of Pathology and the Journal of Clinical Oncology.
Ph.D., Chief Scientist Officer, N-of-One
As an early member of the N-of-One team, Dr. Elkin has led the interpretation of thousands of patient cases, establishing a rigorous process for the analysis of scientific and clinical evidence. For the past nine years, Dr. Elkin has taken a lead role in the development of the N-of-One clinical interpretation methodology to support clinicians in identifying therapeutic strategies specific to each patient. Prior to joining N-of-One, Dr. Elkin completed her postdoctoral fellowship at the Massachusetts Institute of Technology’s Center for Cancer Research, where she earned a fellowship from the Leukemia and Lymphoma Society. Dr. Elkin earned her doctorate in Biological and Biomedical Sciences from Harvard Medical School and an A.B. in Biology and Music from Amherst College, graduating Phi Beta Kappa and summa cum laude, with High Distinction in Biology.